Deutsch English Français

Contact

EP2983591

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2983591

EP2983591 - PREDICTIVE AND RESPONSE BIOMARKER FOR TH-302 ANTI-CANCER THERAPY [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 08.02.2019 Database last updated on 18.11.2024
Former	Examination is in progress Status updated on 16.03.2018
Most recent event Tooltip	08.02.2019	Application deemed to be withdrawn	published on 13.03.2019 [2019/11]
Applicant(s)	For all designated states Threshold Pharmaceuticals, Inc. 170 Harbor Way, Suite 300 South San Francisco, CA 94080 / US
	[2016/07]
Inventor(s)	01 / HART, Charles c/o Threshold Pharmaceuticals Inc. 170 Harbor Way Suite 300 South San Francisco, California 94080 / US
	02 / SELICK, Harold E. c/o Threshold Pharmaceuticals Inc. 170 Harbor Way Suite 300 South San Francisco, California 94080 / US
	03 / SUN, Jessica c/o Threshold Pharmaceuticals Inc. 170 Harbor Way Suite 300 South San Francisco, California 94080 / US
	[2016/07]
Representative(s)	Ricker, Mathias Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Partnerschaft mbB Zweibrückenstraße 5-7 80331 München / DE
	[N/P]
Former [2016/07]	Ricker, Mathias Wallinger Ricker Schlotter Tostmann Patent- und Rechtsanwälte Zweibrückenstrasse 5-7 80331 München / DE
Application number, filing date	14783066.5	09.04.2014
	[2016/07]
	WO2014US33491
Priority number, date	US201361810643P	10.04.2013 Original published format: US 201361810643 P
	[2016/07]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2014169035
	Date:	16.10.2014
	Language:	EN
	[2014/42]
	Type:	A1 Application with search report
	No.:	EP2983591
	Date:	17.02.2016
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 16.10.2014 takes the place of the publication of the European patent application.
	[2016/07]
Search report(s)	International search report - published on:	KR	16.10.2014
	(Supplementary) European search report - dispatched on:	EP	29.11.2016
Classification	IPC:	A61B6/03, A61K31/675, A61K49/00, A61K51/04	[2016/52]
	CPC:	A61K31/675 (EP,US); A61K51/0453 (EP,US); A61P35/00 (EP); A61P35/02 (EP); A61B6/037 (EP,US)
	Former IPC [2016/07]	A61B6/03, A61K31/675, A61K49/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/07]
Title	German:	PRÄDIKTIVER UND ANSPRECHBIOMARKER FÜR TH-302-KREBSTHERAPIE	[2016/07]
	English:	PREDICTIVE AND RESPONSE BIOMARKER FOR TH-302 ANTI-CANCER THERAPY	[2016/07]
	French:	BIOMARQUEUR DE PRÉDICTION ET DE RÉPONSE POUR UNE THÉRAPIE ANTICANCÉREUSE PAR TH-302	[2016/07]
Entry into regional phase	06.11.2015	National basic fee paid
	06.11.2015	Search fee paid
	06.11.2015	Designation fee(s) paid
	06.11.2015	Examination fee paid
Examination procedure	06.11.2015	Examination requested [2016/07]
	26.06.2017	Amendment by applicant (claims and/or description)
	14.03.2018	Despatch of a communication from the examining division (Time limit: M06)
	25.09.2018	Application deemed to be withdrawn, date of legal effect [2019/11]
	23.10.2018	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/11]
Fees paid	Renewal fee
	13.09.2016	Renewal fee patent year 03
	10.04.2017	Renewal fee patent year 04
	11.04.2018	Renewal fee patent year 05
	Penalty fee
	Additional fee for renewal fee
	30.04.2016	03 M06 Fee paid on 13.09.2016
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[I]WO2012006032 (THRESHOLD PHARMACEUTICALS INC [US], et al) [I] 1-8 * paragraph [0097] * * paragraph [0100]; claims 1, 5, 6 * * paragraph [0103] *;
		[I]WO2012009288 (THRESHOLD PHARMACEUTICALS INC [US], et al) [I] 1-8 * paragraph [0073] * * paragraph [0076] * * paragraph [0081] * * paragraph [0083] - paragraph [0090] *;
		[A]WO2012008860 (AUCKLAND UNISERVICES LTD [NZ], et al) [A] 1-8 * page 7, line 3 - page 9, line 10 *;
		[A] - QIAN LIU ET AL, "TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, (20120302), vol. 69, no. 6, doi:10.1007/S00280-012-1852-8, ISSN 1432-0843, pages 1487 - 1498, XP035062681 [A] 1-8 * page 1526, column 2, line 8 - line 13 * DOI: http://dx.doi.org/10.1007/s00280-012-1852-8
		[A] - J. HU ET AL, "Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug", BLOOD, US, (20100902), vol. 116, no. 9, doi:10.1182/blood-2010-02-269126, ISSN 0006-4971, pages 1524 - 1527, XP055321592 [A] 1-8 * page 1495, column 1, line 24 - column 2, line 6 * DOI: http://dx.doi.org/10.1182/blood-2010-02-269126
	International search	[Y]WO2010048330 (THRESHOLD PHARMACEUTICALS INC [US], et al);
		[X]WO2012006032 (THRESHOLD PHARMACEUTICALS INC [US], et al);
		[A]US2007117784 (CLELAND JEFFREY L [US], et al);
		[A]WO2012008860 (AUCKLAND UNISERVICES LTD [NZ], et al);
		[A]US2003091574 (GEVAS PHILIP C [US], et al)

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p